Wei Zheng
MD, PhD; Editor in Chief, Alpha Psychiatry; Department of Psychiatry, The Affiliated Brain Hospital of Guangzhou Medical University
Data updated
Research Footprint
Wei Zheng appears in 7 tracked papers (2018–2022), most studied alongside Ketamine and Placebo, across Depressive Disorders, Bipolar Disorder and Major Depressive Disorder (MDD).
Most-cited paper: Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression (179 citations).
Frequent co-authors: Yanling Zhou, Chengyu Wang and Yuping Ning.
Background & Research
Wei Zheng is a psychiatrist and researcher based at The Affiliated Brain Hospital of Guangzhou Medical University in Guangzhou, China. His work has focused on ketamine treatment for treatment-resistant depression and related outcomes such as anhedonia, cognition, suicidal ideation, and biomarker responses. He also serves as Editor in Chief of Alpha Psychiatry.
Key Impact
He is a clinician-researcher publishing influential clinical studies on repeated intravenous ketamine for depression, including anhedonia, suicidality, cognition, and biomarkers like BDNF and VEGF.
Collaboration Network
7 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Wei Zheng is associated with.